A year ago, Eli Lilly & Co. was poised to become the first pharmaceutical company to register a trillion-dollar market ...

Wall Street looks to stabilise after last week’s tariff-driven slump, with investors gearing up for a crucial week packed ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Major pharmaceutical companies facing patent cliffs and pipeline gaps may view Viking as an attractive acquisition target if clinical data proves successful. 10 stocks we like better than Viking ...

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

Novo Nordisk is misunderstood by the market, creating a rare asymmetric value opportunity. Read why I rate NVO stock a Buy ...

When it was riding high, Novo Nordisk could have done M&A to reduce its dependence on obesity treatments. It didn’t.

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

Trade deficit data, Federal Reserve officials' remarks, earnings from Pfizer, Disney, Uber, and additional companies.

The pharmaceutical industry continues to evolve rapidly, driven by innovation, global health challenges, and technological ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...